New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients

Pharmacogenomics

Volumn 14, Issue 6, 2013, Pages 631-640

  Zabala, William ^a,b   Cruz, Raquel ^c   Barreiro De Acosta, Manuel ^d   Chaparro, María ^e   Panes, Julián ^f   Echarri, Ana ^g   Esteve, Maria ^h   Carpio, Daniel ⁱ   Andreu, Montserrat ^j   García Planella, Esther ^k   Domenech, Eugeni ^l   Carracedo, Angel ^a,c   Gisbert, Javier P ^e   Barros, Francisco ^a,c  

^a Fundacion Publica Galega de Medicina Xenomica   (Spain)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g Universidad de La Coruña   (Spain)

^h HOSPITAL MÚTUA DE TERRASSA   (Spain)

ⁱ HOSPITAL MONTECELO   (Spain)

^j HOSPITAL DEL MAR   (Spain)

^k HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^l HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

inflammatory bowel disease; myelotoxicity; pharmacogenetics; thiopurine

Indexed keywords

AZATHIOPRINE; CYTOKINE; INTERLEUKIN 6; METALLOPROTEINASE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHILD; COCHRAN MANTEL HAENSZEL TEST; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; EXTRACELLULAR MATRIX; FEMALE; FSTL5 GENE; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; IL6ST GENE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; TPMT GENE; ULCERATIVE COLITIS; VALIDATION STUDY;

ALLELES; BONE MARROW DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOKINE RECEPTOR GP130; FOLLISTATIN-RELATED PROTEINS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PURINES; SULFHYDRYL COMPOUNDS;

EID: 84875979229     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.38     Document Type: Article

References (45)

1. Poppe D, Tiede I, Fritz G et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176, 640-651 (2006). (Pubitemid 43023313)
2. Pearson DC, May GR, Fick GH et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann. Intern. Med. 123, 132-142 (1995).
3. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am. J. Gastroenterol. 103, 1783-1800 (2008).
4. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 61, 136-146 (2000).
5. Relling MV, Gardner EE, Sandborn WJ et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89, 387-391 (2011).
6. Gisbert JP, Gomollon F, Cara C et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig. Dis. Sci. 52, 1262-1269 (2007). (Pubitemid 46626159)
7. Colombel J, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118, 1025-1030 (2000). (Pubitemid 30346978)
8. Gisbert JP, Gonzalez-Lama Y, Mate J. Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease. Gastroenterol. Hepatol. 29, 568-583 (2006). (Pubitemid 44902306)
9. Duley JA, Somogyi AA, Martin JH. The future of thiopurine pharmacogenomics. Pharmacogenomics 13, 1549-1552 (2012).
10. Stocco G, Martelossi S, Barabino A et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13, 57-64 (2007). (Pubitemid 46080010)
11. Lennard-Jones J. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. 24, 2-6 (1989). (Pubitemid 20015811)
12. Wang K, Li W-D, Zhang CK. Genome-wide association study on obesity and obesity-related traits. PLoS ONE 6, e18939 (2011).
13. Ansari A, Hassan C, Duley J et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16, 1743-1750 (2002).
14. Anderson CA, Petterssohn FH, Clarke GM et al. Data quality control in genetic case-control association studies, Nat. Protoc. 5, 1564-1573 (2010).
15. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007). (Pubitemid 47330214)
16. Gonzalez JR, Armengol L, Sole X et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23, 644-645 (2007). (Pubitemid 46522604)
17. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 155, 945-959 (2000). (Pubitemid 30397141)
18. Mantel N. Chi-square tests with 1 degree of freedom-extensions of the Mantel-Haenszel procedure. J. Am. Stat. Assoc. 58, 690-700 (1963).
19. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 20, 1149-1157 (2005). (Pubitemid 41602556)
20. Gisbert JP, Gomollon F, Mate J et al. Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyl-transferase (TPMT) activity. Rev. Clin. Esp. 202, 555-562 (2002). (Pubitemid 35277186)
21. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 51, 143-146 (2002). (Pubitemid 34791433)
22. Van Dieren J, Van Vuuren A, Kusters J et al. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 54, 1664-1664 (2005).
23. Skiniotis G, Boulanger MJ, Garcia KC et al. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat. Struct. Mol. Biol. 12, 545-551 (2005). (Pubitemid 43085886)
24. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 76, 253-262 (1994). (Pubitemid 24046688)
25. Silver JS, Hunter CA. Gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leukoc. Biol. 88, 1145-1156 (2010).
26. Fasnacht N, Muller W. Conditional gp130 deficient mouse mutants. Semin. Cell Dev. Biol. 19, 379-384 (2008).
27. Hirota H, Chen J, Betz UA et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97, 189-198 (1999). (Pubitemid 29194270)
28. Tebbutt NC, Giraud AS, Inglese M et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 8, 1089-1097 (2002). (Pubitemid 35175963)
29. Atsumi T, Ishihara K, Kamimura D et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. 196, 979-990 (2002).
30. Nakagawa T, Tsuruoka M, Ogura H et al. IL-6 positively regulates Foxp3+CD8+ T cells in vivo. Int. Immunol. 22, 129-139 (2010).
31. Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig. Liver Dis. 42(Suppl. 3), S235-S241 (2010).
32. Schlerman FJ, Bree AG, Kaviani MD et al. Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates. Stem Cells 14, 517-532 (1996). (Pubitemid 26322113)
33. Hao J, Sun L, Huang H et al. Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys. Radiat. Res. 162, 157-163 (2004). (Pubitemid 39100015)
34. Momose K, Taguchi K, Saitoh M et al. Effects of interleukin-11 on the hematopoietic action of granulocyte colony-stimulating factor. Arzneimittelforschung 52, 857-861 (2002). (Pubitemid 35398737)
35. Pellegrini M, Marcotte EM, Thompson MJ et al. Assigning protein functions by comparative genome analysis: protein phylogenetic profiles. Proc. Natl Acad. Sci. USA 96, 4285-4288 (1999). (Pubitemid 29190328)
36. Ghaderian SM, Akbarzadeh Najar R, Tabatabaei Panah AS. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron. Artery Dis. 21, 330-335 (2010).
37. Wang LE, Huang YJ, Yin M et al. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur. J. Cancer 47, 107-115 (2011).
38. Fang WL, Liang WB, He H et al. Association of matrix metalloproteinases 1, 7, and 9 gene polymorphisms with genetic susceptibility to colorectal carcinoma in a Han Chinese population. DNA Cell Biol. 29, 657-661 (2010).
39. Chaudhary AK, Pandya S, Mehrotra R et al. Functional polymorphism of the MMP-1 promoter (-1607 1G/2G) in potentially malignant and malignant head and neck lesions in an Indian population. Biomarkers 15, 684-692 (2010).
40. Nam SI, Yu GI, Kim HJ et al. A polymorphism at-1607 2G in the matrix metalloproteinase-1 (MMP-1) increased risk of sudden deafness in Korean population but not at-519A/G in MMP-1. Laryngoscope 121, 171-175 (2011).
41. Odenbach J, Wang X, Cooper S et al. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 57, 123-130 (2011).
42. Planaguma J, Liljestrom M, Alameda F et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum. Pathol. 42, 57-67 (2011).
43. Garavello W, Maggioni D, Nicolini G et al. Association between metalloproteinases 2 and 9 activity and ERK1/2 phosphorylation status in head and neck cancers: an ex vivo study. Oncol. Rep. 24, 1073-1078 (2010).
44. Tsagaraki I, Tsilibary EC, Tzinia AK. TIMP-1 interaction with alphavbeta3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF-alpha-induced apoptosis. Cell Tissue Res. 342, 87-96 (2010).
45. Qu P, Yan C, Du H. Matrix metalloproteinase 12 overexpression in myeloid lineage cells plays a key role in modulating myelopoiesis, immune suppression, and lung tumorigenesis. Blood 117, 4476-4489 (2011).